Cargando…
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling
BACKGROUND: Pancreatic cancer remains one of the most rapidly progressive and deadly malignancies worldwide. Current treatment regimens only result in small improvements in overall survival for patients with this cancer type. CPI-613 (Devimistat), a novel lipoate analog inhibiting mitochondrial meta...
Autores principales: | Gao, Lixia, Xu, Zhigang, Huang, Zheng, Tang, Yan, Yang, Donglin, Huang, Jiuhong, He, Leilei, Liu, Manran, Chen, Zhongzhu, Teng, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187515/ https://www.ncbi.nlm.nih.gov/pubmed/32345326 http://dx.doi.org/10.1186/s13046-020-01579-x |
Ejemplares similares
-
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism
por: Kumstel, Simone, et al.
Publicado: (2022) -
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy
por: Khan, Husain Yar, et al.
Publicado: (2022) -
Smart Design of Mitochondria-Targeted and ROS-Responsive CPI-613 Delivery Nanoplatform for Bioenergetic Pancreatic Cancer Therapy
por: Zhang, Yi-Mei, et al.
Publicado: (2021) -
A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer
por: Alistar, Angela, et al.
Publicado: (2017) -
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
por: Bellio, Chiara, et al.
Publicado: (2019)